Intralytix, Inc.'s ShigActive™ bacteriophage therapy targeting Shigella has entered a Phase 1/2a clinical trial at the Center for Vaccine Development at the University of Maryland, Baltimore School of Medicine in Baltimore, MD. The trial, registered under clinicaltrials.gov NCT05182749, is currently active, but not recruiting healthy volunteers for Phase 2a.